EPIX
ESSA Pharma Inc.0.2012
+0.0000+0%
Oct 8, 4:00:01 PM EDT
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
9.52MP/E (TTM)
-Basic EPS (TTM)
-0.57Dividend Yield
0%Recent Filings
8-K
Acquisition closed; delisting next.
ESSA Pharma closed its acquisition by XenoTherapeutics' subsidiary on October 9, 2025, via a plan of arrangement. Shareholders received US$0.1242 per share plus one CVR potentially worth up to US$0.14, totaling up to US$6.7M aggregate based on contingent liabilities. Trading halts October 10; ESSA now a wholly owned subsidiary. Control shifted fast.
8-K
Securityholders approve Xeno acquisition
ESSA Pharma securityholders overwhelmingly approved its acquisition by XenoTherapeutics via statutory plan of arrangement on October 3, 2025, with 99.8% votes for across classes. Shareholders also backed executive compensation and contingency liquidation plans. Court approval awaits October 7; close eyed for October 9. Litigation risks loom.
8-K
Class action filed against ESSA
ESSA Pharma faces a putative class action lawsuit filed September 30, 2025, in California Superior Court by Nathan O'Neil et al., alleging breach of contract over its August 14, 2025 8-K disclosures tied to an August 25 press release. The suit targets buyers of common shares on August 25. Company plans vigorous defense. Outcome not estimable.
8-K
ESSA advances acquisition timeline
ESSA Pharma secured an amended Interim Order from the Supreme Court of British Columbia on September 25, 2025, greenlighting its special meeting on October 3 to vote on the acquisition by non-profit XenoTherapeutics. The order sets dissent notices due October 1 and final court approval hearing for October 7. Timeline advances the deal. Yet risks like litigation and disruptions loom large.
8-K
ESSA cuts deal payout sharply
ESSA Pharma amended its business combination agreement with XenoTherapeutics on September 23, 2025, slashing upfront cash to shareholders to US$0.12 per share from US$1.91 originally estimated—after a prior US$1.69 distribution—while capping CVRs at US$0.14 each (up to US$6.7M aggregate), citing liabilities and low cash estimates. The special meeting adjourns to October 3. Payouts now hinge on contingencies.
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
BCAX
Bicara Therapeutics Inc.
18.15-0.21
BIOE
Bio Essence Corp.
0.05+0.00
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
ESSI
Eco Science Solutions, Inc.
0.01+0.00
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
ONCO
Onconetix, Inc.
1.94-0.04
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
TTNP
Titan Pharmaceuticals, Inc.
4.61-0.18